Clinical Trial Update: Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17 [NA]

View source ↗

Summary

A recruiting clinical trial evaluating whether adding fiber supplementation to anti-IL-17 antibody therapy can correct treatment-related gut dysbiosis in axial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Drugs mentioned

• anti-IL-17 antibody therapy

Snippet

Sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Axial Spondyloarthritis | NA | Status: RECRUITING